[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Medical Research Radiological Centre of the Ministry of Health of Russia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100623704","phase-2-neoadjuvant-chemoimmunotherapy-camrelizumab--paclitaxel--carboplatin-for-resectable-hnscc-100623704",false,"NCT07400094","Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC","Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)","NeoCamre-HN","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the oral cavity and\u002For larynx, Stage III-IVA (cT1-2N1-2M0, cT3-4aN0-2M0)\n* Resectable disease planned for surgical treatment\n* Age 18-75 years\n* No prior antitumor therapy for the current diagnosis\n* Tumor sample available for PD-L1 expression assessment\n* No other malignancies in anamnesis (except basal cell carcinoma of skin and carcinoma in situ of cervix)\n* Absence of comorbidities preventing systemic chemotherapy and immunotherapy\n\nExclusion Criteria:\n\n* Patient refusal to undergo planned treatment\n* Protocol violations not related to medical indications","ALL","18 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA) squamous cell carcinoma of the oral cavity and\u002For larynx.\n\nFifty patients will receive 3 cycles of therapy (camrelizumab 200 mg IV, paclitaxel 175 mg\u002Fm2 IV, carboplatin AUC6 IV, Day 1 every 21 days) followed by radical surgery 4-6 weeks later. Patients are then stratified to risk-adapted adjuvant therapy based on pathological findings (radiation or chemoradiation with cisplatin if adverse features present).\n\nThe primary endpoint is the pathological complete response (pCR) rate and major pathological response (MPR, \\\u003C10% viable tumor cells) rate at surgery. Secondary endpoints include objective response rate (ORR) by imaging (MRI\u002FPET-CT), correlation of PET-CT metabolic response with pathological response, proportion requiring adjuvant chemoradiation, and 3-year event-free survival compared to historical controls.\n\nStudy period: 2026-2029.",[28,29,30],"Squamous Cell Carcinoma of Head and Neck","Laryngeal Neoplasms","Oral Cavity Neoplasm",[32,33,34,35,36,37,38],"Head and Neck Squamous Cell Carcinoma","Neoadjuvant Therapy","Camrelizumab","Paclitaxel","Carboplatin","Pathological Complete Response","PD-1 Inhibitor","NOT_YET_RECRUITING","2026-02-03",{"date":42,"type":43},"2026-02-10","ACTUAL",{"date":45,"type":22},"2026-02",{"date":47,"type":22},"2029-02",{"name":49,"class":50},"National Medical Research Radiological Centre of the Ministry of Health of Russia","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100591724","phase-2-nivo40-avd-for-advanced-classic-hodgkin-lymphoma-100591724","NCT06984146","Nivo40-AVD for Advanced Classic Hodgkin Lymphoma","Flat-dose Nivolumab (40 mg) in Combination With Doxorubicin, Vinblastine, and Dacarbazine (AVD) for Newly Diagnosed Advanced Classic Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma\n2. No past history of autoimmune disease\n3. Age \\> 18 years\n4. Ejection fraction \\> 50%\n5. ECOG 0-4\n\nExclusion Criteria:\n\n1. Organ failure (e.g. creatinine \\> 2x ULN; ALT or AST \\> 5x ULN; bilirubin \\> 2x ULN; hemodynamic instability; respiratory failure \\> Grade 1)\n2. Uncontrolled infection\n3. Pregnancy\n4. Inability to sign informed consent",{"count":60,"type":22},54,[25],"The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma",[64],"Hodgkin Lymphoma, Adult","RECRUITING","2025-11-20",{"date":68,"type":43},"2025-11-26",{"date":70,"type":43},"2025-04-15",{"date":72,"type":22},"2029-01",{"name":49,"class":50},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":51},"100581922","phase-2-oligo-10-stereotactic-ablative-radiation-therapy-for-metastatic-patients-with-6-to-10-metastatic-sites-100581922","NCT06856603","OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites","OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients (6-10 Metastases): A Prospective Phase II Single-Arm Trial","OLIGO-10","Inclusion Criteria:\n\n* ECOG status 0-3\n* Persistent or progressive cancer disease with 6 to 10 metastases\n* ≤ 5 metastases in one organ\n* Life expectancy \\> 6 months for intracranial lesions\n* Inability to surgically resect all metastatic lesions\n* Positive tumor board decision for trial inclusion\n* Signed informed consent\n\nExclusion Criteria:\n\n* ECOG status 4\n* De novo metastatic disease\n* Radiological complete response after drug therapy\n* Brain metastasis only\n* Brain metastasis \\> 3 cm, requiring neurosurgery\n* Size of any metastasis \\> 5 cm\n* Previous radiation therapy for any metastatic site\n* Leptomeningeal, pleural, or peritoneal carcinomatosis\n* Spinal cord compression, requiring neurosurgery\n* Invasion of great vessels, skin, or GI tract\n* Negative tumor board decision for trial inclusion\n* Unsigned informed consent",{"count":21,"type":22},[25],"Currently, the standard of care for patients with diagnosed metastatic cancer is drug therapy (chemotherapy, targeted therapy, or immunotherapy). However, the approach to oligometastatic disease (1-5 metastases) is evolving. An increasing number of de novo, persistent, and progressive oligometastatic tumors are now being treated with curative intent, with radiation therapy among the most effective treatment options, applied to metastatic sites in ablative doses. Emerging results from the SABR-COMET 3 and 5 trials, which investigate stereotactic ablative radiotherapy for patients with 1-3 and 1-5 metastatic sites, demonstrate a clear improvement in overall survival. However, patients with more than five metastases remain in a gray area.\n\nThe aim of our study is to assess the safety and effectiveness of radiation treatment for patients with tumors of various localizations and 6 to 10 metastases in the bones and internal organs. Stereotactic radiation therapy will be applied to patients with persistent or progressive metastatic forms of tumors, without changing their ongoing drug therapy regimen.",[86],"Metastatic Disease",[86,88,89,90,91],"Stereotactic radiation therapy","Stereotactic body radiation therapy","Stereotactic ablative radiation therapy","Oligometastatic Disease","2025-02-28",{"date":94,"type":43},"2025-03-04",{"date":96,"type":43},"2025-02-07",{"date":98,"type":22},"2030-12-31",{"name":49,"class":50},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":51},"100558855","phase-2-stereotactic-radiotherapy-for-oligometastasis-1-5-in-various-tumor-sites-vs-palliative-care-100558855","NCT06556550","Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care","Stereotactic Radiation Therapy for Oligometastasis (1-5) in Various Tumor Sites in Comparison to Palliative Care of Oligometastatic Tumors.","Inclusion Criteria:\n\n1. Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64).\n2. 0-2 points on the WHO\u002FECOG scale of assessment of the general condition of the patient.\n3. The absence of disease progression after the current line of chemotherapeutic treatment.\n4. The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion.\n5. The total number of distant metastases is no more than 5.\n6. Life expectancy of more than 6 months for brain metastases (GPA-score)\n7. The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design.\n8. Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist.\n9. Signed informed consent\n\nExclusion Criteria:\n\n1. 3-4 points on the WHO\u002FECOG scale of assessment of the general condition of the patient\n2. The complete response of all foci to the chemotherapy.\n3. Distant metastases only in the brain, without damage to bones and other organs.\n4. Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment.\n5. Distant metastasis in the brain stem and spinal cord.\n6. The size of at least one distant metastasis is more than 5 cm.\n7. Previously performed radiation therapy on one of the metastatic foci.\n8. Metastatic lesion of the pleura, membranes of the brain or peritoneum.\n9. The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design.\n10. Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin.\n11. Compression of the spinal cord by distant metastasis according to instrumental studies.",{"count":108,"type":22},100,[25,110],"PHASE3","Currently, the usual standard of palliative treatment used in patients with diagnosed oligometastatic cancer in accordance with the local clinical recommendations is chemotherapy and\u002For a symptomatic course of radiation therapy in doses less than ablative ones The aim of the study is to increase the effectiveness of treatment of patients with tumors of various localizations with oligometastases in the bones and internal organs with the help of stereotactic radiation therapy.\n\nThe method of stereotactic radiation therapy will be applied in patients with oligometastatic forms of tumors of various localizations after the current line of chemotherapy treatment T1-4, N0-3, M0-1, over 18 years of age at the start of treatment, compared with standard methods of palliative therapy in those same patient models.",[91],[114,115,116,91],"stereotactic radiation therapy","stereotactic body radiation therapy","stereotactic ablative radiation therapy","2024-08-13",{"date":119,"type":43},"2024-08-16",{"date":121,"type":43},"2024-05-31",{"date":123,"type":22},"2029-12-31",{"name":49,"class":50},""]